adivo GmbH and Bayer Ani­mal Health GmbH have signed a global collaboration agreement to develop therapeutic antibodies for veterinary medicine. Under the terms of the agreement, Bayer Animal Health will have access to adivo’s species-specific monoclonal antibody technology. Financial terms were not disclosed. adivo and Bayer Animal Health have agreed to jointly discover and develop species-specific therapeutic monoclonal antibodies that address the demand for innovative therapies for household pets. The companies aim to provide veterinarians with new and innovative treatments that address unmet medical needs of their animal patients. adivo will select species-specific antibodies using its proprietary fully canine phage display library. Bayer Animal Health will provide targets associated with severe animal ­diseases.